A new model for delivering care for lower urinary tract symptoms.

Introduction: Lower urinary tract symptoms (LUTS) are being treated in secondary care settings, resulting in delayed access for all patients. The objectives of this study were to examine the effects of an integrated delivery model on 1) the volume of care delivered in the secondary care setting; and 2) the use of potentially unnecessary care associated with LUTS.

Methods: This study was based on a retrospective analysis of administrative data collected before and after the integrated LUTS clinic was introduced in Calgary, Alberta.

Case distribution and complications of mid-urethral sling surgery in a Canadian city before and after the Health Canada advisory on pelvic floor mesh.

Introduction And Hypothesis: Increased incidences of complications related to the use of mid-urethral slings (MUS) for the treatment of stress urinary incontinence resulted in both the Food and Drug Administration (FDA) and Health Canada issuing advisories in 2008 and 2010 respectively. The purpose of this study was to assess the effect these advisories had on the number of surgeons performing MUS surgery and post-surgical complications in Calgary, Canada.

Methods: In this study, we conducted a retrospective analysis of administrative data between 2006 and 2011.

OnabotulinumtoxinA for the treatment of idiopathic overactive bladder is effective and safe for repeated use.

Introduction: The objective of this study was to compare efficacy and safety outcomes between patients receiving onabotulinum-toxinA (OnabotA) for the first time and those receiving a repeat injection.

Methods: Data collected before and after OnabotA injection were extracted from a clinical registry. Patients were classified into either first or repeat injection subgroups.

A clinical perspective on electronically collecting patient-reported outcomes at the point-of-care for overactive bladder.

Introduction: Collecting patient-reported outcomes (PROs) can inform the treatment and management of overactive bladder (OAB). However, collecting these data at the point-of-care can be time-consuming and have a negative impact on a clinic's workflow. The purpose of this study was to pilot a digital system for collecting PROs at the point-of-care and qualitatively assess clinicians' perspectives in terms of the system's impact on the delivery of care for OAB.

The use of intra-detrusor onabotulinumtoxinA in patients with myasthenia gravis.

The use of intra-detrusor onabotulinumtoxinA (Botox) in patients with myasthenia gravis has not been reported, and little evidence exists to substantiate a complete contraindication of Botox use in this population. Here, we present two cases of comorbid overactive bladder (OAB) and myasthenia gravis successfully treated with intra-detrusor Botox.